VERAXA Biotech AG listed on the Nasdaq stock exchange and appointed Carl von Halem as Interim Chief Financial Officer.
2 reports, 2 independent
Updated Sep 9
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
VERAXA Biotech AG listed on the Nasdaq stock exchange and appointed Carl von Halem as Interim Chief Financial Officer.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Raju Willener joins VERAXA Biotech AG as CFO to advance the company's oncology pipeline.1 source
VERAXA Biotech AG listed on Nasdaq and appointed Carl von Halem as Interim CFO.1 source
Keep exploring
Part of
A company was listed on the Nasdaq stock exchange earlier this month.Also in this story
- Village Super Market, Inc. is operating on the Nasdaq stock exchange.
- CeriBell, Inc. was listed on the Nasdaq stock exchange, with its prognosis potential validated by an AI algorithm.
- MacKenzie Realty Capital, Inc. is listed on Nasdaq and filed disclosures with the SEC.
- BOND, headquartered in New York City, is listed on the Nasdaq stock exchange.
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- A company, likely Health Catalyst, was listed on the Nasdaq stock exchange, and Tami Reller was appointed to the board of directors.
- HCW Biologics announced it is listed on the Nasdaq stock exchange.
- Abivax SA stock traded on the Nasdaq exchange, and the company appointed Tim Kelly as chief technical officer.
- Evelo Biosciences listed its stock on the Nasdaq exchange on August 1, 2026.
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.